Analyzing 133 patients treated with CD19/CD22 CAR-T cells, Sheth et al. developed a model to identify patients with grade ≥ 4 CRS as developing a fever ≥ 38.9 °C within CAR-T cell administration in conjunction with serum MCP-1 concentration ≥ 1343.5 pg/mL [145]. The gene discussed is CD19; the disease is congenital rubella syndrome.